Proteomic Characterization of Urinary Extracellular Vesicles from Kidney-Transplanted Patients Treated with Calcineurin Inhibitors

Laura Carreras-Planella 1,2, Javier Juega 1,3,4, Omar Taco 3,4, Laura Cañas 1,3,4, Marcella Franquesa 1,4*, Ricardo Lauzurica 1,4,5 and Francesc Enric Borràs 1,2,3,5,*

1 REMAR-IVECAT Group, Can Ruti Campus, Germans Trias i Pujol Health Science Research Institute, 08916 Badalona, Spain; lcarreras@igtp.cat (L.C.-P.); juega.javier@gmail.com (J.J.);
laucanyas78@hotmail.com (L.C.); mfranquesa@igtp.cat (M.F.); rlauzurica.germanstrias@gencat.cat (R.L.)
2 Department of Cell Biology, Physiology and Immunology, Autonomous University of Barcelona, Bellaterra, 08193 Cerdanyola del Vallès, Spain
3 Autonomous University of Barcelona, Bellaterra, 08193 Cerdanyola del Vallès, Spain;
oetaco.germanstrias@gencat.cat
4 Nephrology Department, Can Ruti Campus, Germans Trias i Pujol University Hospital, 08916 Badalona, Spain
5 Instituto de Salud Carlos III, Red de Investigación Renal (ISCIII-REDinREN RD16/0009 Feder Funds), 28029 Madrid, Spain
* Correspondence: feborras@igtp.cat

Received: 10 September 2020; Accepted: 12 October 2020; Published: 14 October 2020

Abstract: Use of immunosuppressive drugs is still unavoidable in kidney-transplanted patients. Since their discovery, calcineurin inhibitors (CNI) have been considered the first-line immunosuppressive agents, in spite of their known nephrotoxicity. Chronic CNI toxicity (CNIT) may lead to kidney fibrosis, a threatening scenario for graft survival. However, there is still controversy regarding CNIT diagnosis, monitoring and therapeutic management, and their specific effects at the molecular level are not fully known. Aiming to better characterize CNIT patients, in the present study, we collected urine from kidney-transplanted patients treated with CNI who (i) had a normal kidney function, (ii) suffered CNIT, or (iii) presented interstitial fibrosis and tubular atrophy (IFTA). Urinary extracellular vesicles (uEV) were enriched and the proteome was analyzed to get insight into changes happening during CNI. Members of the uroplakin and plakin families were significantly upregulated in the CNIT group, suggesting an important role in CNIT processes. Although biomarkers cannot be asserted from this single pilot study, our results evidence the potential of uEV as a source of non-invasive protein biomarkers for a better detection and monitoring of this renal alteration in kidney-transplanted patients.

Keywords: exosomes; renal transplantation; tacrolimus; cyclosporine A; proteomics

1. Introduction

The calcineurin inhibitors (CNI) cyclosporine A [1,2] and tacrolimus have become the current first-line immunosuppressive agents in kidney transplantation [3–5] for more than 30 years. Their main mechanism of action is based on the disruption of T-cell activation and proliferation by inhibiting calcineurin, the enzyme responsible of the dephosphorylation and activation of NFATc that triggers the transcription of interleukin (IL)-2. Hampering IL-2/IL2R interaction reduces T-cell activation and proliferation, a crucial step in graft rejection [6]. About 94% of renal-transplanted patients receive a CNI-based immunosuppressive regime [7], yet it is well-known that CNI treatment can produce nephrotoxicity, commonly referred to as CNI toxicity (CNIT) [8]. There is still controversy
in the diagnosis, monitoring, and therapeutic management of CNIT (reviewed in [9]). Acute CNIT (aCNIT) is histologically associated with the appearance of isometric vacuolization of the tubular epithelium [10–12], while chronic CNI (cCNIT) produces chronic renal lesions such as interstitial fibrosis, tubular atrophy, arteriolar hyalinosis, and glomerulosclerosis [13,14], all contributing to the progressive and irreversible deterioration of the renal function and graft-loss [15,16]. To avoid this scenario, CNI levels in patients should be maintained within a narrow therapeutic window, a big challenge due to the high inter- and intraindividual pharmacokinetic variability of these drugs [17,18]. There are currently no specific markers of CNIT, and tacrolimus or cyclosporine A trough levels not always correlate with CNIT [19].

Urinary extracellular vesicles (uEV) have been shown to carry proteins that reflect the pathophysiological state of cells in the urinary system [20]. Thus, the analysis of uEV can shed light on the pathophysiological processes occurring in the kidney and as well as providing a source of non-invasive biomarkers of renal alterations. With the aim of characterizing CNIT in renal transplantation, we collected urine samples and isolated uEV from kidney-transplanted patients (all treated with CNI) that were classified into: (i) normal kidney function (NKF), (ii) CNIT, or (iii) interstitial fibrosis and tubular atrophy (IFTA). The uEV proteome was characterized by mass-spectrometry.

2. Results

2.1. Patients and Samples

In this study, size-exclusion chromatography (SEC)-isolated uEV samples from three groups of kidney-transplanted patients (NKF, IFTA, and CNIT) were used. Table 1 summarizes the clinical data of each patient when urine sample was collected. As expected, patients in the NKF group presented significantly lower serum creatinine levels than IFTA ($p = 0.012$) and CNIT ($p = 0.012$), but no other significant differences were found. Patient C10, the unique patient affected by chronic CNIT, presented the highest serum creatinine level. Table 2 summarizes the induction treatment at kidney transplantation, immunosuppression regime at sample’s collection and the diagnosis based on renal biopsy and clinical parameters. All patients were receiving an immunosuppressive regime consisting of prednisone and a calcineurin inhibitor (in most cases tacrolimus, only one patient in each group was receiving cyclosporine A), with or without mycophenolate mofetil. The histopathological results of the Banff scoring are summarized in Supplementary Table S1 and representative histological photographs are displayed in Supplementary Figure S1. Acute CNIT was diagnosed in four out of five cases by the presence of isometric vacuolization of the tubular epithelium and the preservation of the microvilli on the apical border. The other CNIT patient was diagnosed with chronic CNIT because of the presence of grade 3 arteriolar hyalinosis and circumferential hyalinosis with peripheric nodules. The diagnosis of CNIT was further supported by the high blood levels of tacrolimus, determined according to the study by Cosio et al. [21] or high blood levels of cyclosporine A based on the Symphony study [22]. Patients in the IFTA group presented different grades of fibrosis in the renal biopsy with no other signs of pathology. The determination of IFTA grade was based on the mean values of the Banff parameters chronic interstitial and tubular lesions (ci and ct). Also, IFTA patients showed lower blood levels of tacrolimus and cyclosporine A compared to CNIT patients, and similar to NFK patients. Patient I13 suffered a previous episode of acute cellular rejection and one episode of acute humoral rejection 21 and 9 months before urine collection, respectively. This patient showed no histopathological signs of rejection at sample collection and was therefore included in the study.
### Table 1. Clinical parameters of the study patients at urine collection.

| Group, Sample | Age | Gender | DM | HT | Crea. | Prot. | Months from RT | LD | Donor Age |
|---------------|-----|--------|----|----|-------|-------|----------------|----|------------|
| N1            | 64  | F      | −  | −  | 0.86  | 99    | 137.9         | −  | 53         |
| N2            | 65  | M      | −  | +  | 0.86  | 110   | 186.6         | −  | 37         |
| N3            | 45  | F      | −  | +  | 0.82  | 30    | 113.6         | −  | 43         |
| N4            | 42  | M      | −  | +  | 0.89  | 187   | 186.6         | −  | 30         |
| N5            | 57  | M      | −  | +  | 0.9   | 92    | 166.4         | −  | 45         |
| N6            | 65  | F      | −  | −  | 0.85  | 35    | 70.0          | +  | 37         |
| N7            | 69  | F      | −  | +  | 1.14  | 86    | 57.8          | +  | 58         |
| C8            | 55  | M      | +  | +  | 2.29  | 506   | 0.5           | +  | 62         |
| C9            | 33  | M      | −  | −  | 1.93  | 232   | 2.8           | +  | 59         |
| C10           | 49  | F      | −  | +  | 3.08  | 427   | 238.8         | −  | 45         |
| C11           | 50  | F      | −  | −  | 2.49  | 207   | 5.5           | −  | 60         |
| C12           | 41  | F      | −  | +  | 1.80  | 76    | 25.7          | −  | 34         |
| I13           | 50  | F      | −  | −  | 2.00  | 62    | 21.7          | +  | 48         |
| I14           | 64  | M      | −  | −  | 1.60  | 1600  | 84.6          | −  | 71         |
| I15           | 68  | M      | −  | +  | 2.49  | 94    | 25.8          | −  | 67         |
| I16           | 68  | M      | +  | −  | 2.62  | 800   | 15.1          | −  | 38         |
| I17           | 53  | F      | −  | +  | 2.30  | 806   | 252.3         | −  | 35         |
| Sig.          |     |        |    |    | ns    |       | ns            |    | ns         |

* a Kruskall–Wallis test or b Chi-squared test were performed to determine statistical differences between groups.

N, NKF, C, CNIT; I, IFTA; DM, diabetes mellitus type 2; HT, arterial hypertension; Crea., serum creatinine (mg/dL); Prot., proteinuria (mg/g creatinine); Months from RT., months from renal transplantation until sample collection; LD, living donor; F, female; M, male.

### Table 2. Immunosuppression regime at urine collection.

| Group, Sample | Induction Treatment | IS at Urine Collection | High CNI | Diagnosis |
|---------------|---------------------|------------------------|----------|-----------|
| N1            | IL2RA               | PR, CSA                | −        | NKF       |
| N2            | rATG                | PR, TAC, MMF           | −        | NKF       |
| N3            | IL2RA               | PR, TAC                | −        | NKF       |
| N4            | IL2RA               | PR, TAC                | −        | NKF       |
| N5            | IL2RA               | PR, TAC                | −        | NKF       |
| N6            | IL2RA               | PR, TAC, MMF           | −        | NKF       |
| N7            | IL2RA               | PR, TAC, MMF           | −        | NKF       |
| C8            | IL2RA               | PR, TAC, MMF           | +        | aCNIT     |
| C9            | IL2RA               | PR, TAC, MMF           | +        | aCNIT     |
| C10           | IL2RA               | PR, CSA, MMF           | +        | cCNIT     |
| C11           | IL2RA               | PR, TAC, MMF           | +        | aCNIT     |
| C12           | IL2RA               | PR, TAC, MMF           | +        | aCNIT     |
| I13           | IL2RA               | PR, TAC, MMF           | −        | IFTA (G2) |
| I14           | IL2RA               | PR, TAC, MMF           | −        | IFTA (G1) |
| I15           | IL2RA               | PR, TAC, MMF           | −        | IFTA (G2) |
| I16           | IL2RA               | PR, TAC, MMF           | −        | IFTA (G2) |
| I17           | IL2RA               | PR, CSA                | −        | IFTA (G2) |

IS, immunosuppressive treatment; CNI, calcineurin inhibitors; N, NKF, C, CNIT; I, IFTA; DM, diabetes mellitus type 2; HT, arterial hypertension; Crea., serum creatinine (mg/dL); Prot., proteinuria (mg/g creatinine); Months from RT., months from renal transplantation until sample collection; LD, living donor; F, female; M, male.

### 2.2. Global Analysis of the uEV Proteome

A total of 730 proteins were confidently identified after processing mass spectrometry data. Confirming previous results, and as expected by the enrichment technique used, the FunRich analysis of the identified proteins revealed that the most significantly enriched terms were those related to the secretion of EV such as “vesicle mediated transport” or “extracellular region” according to Gene Ontology (GO)—Biological Process (BP) and Cellular Component (CC) enrichment analysis, respectively (Supplementary Tables S2 and S3).

The number of identified proteins in CNIT samples (mean ± sd, 369 ± 73.9) was significantly higher compared to NKF samples (168.6 ± 65.1) and higher than IFTA samples (246.8 ± 47.0) (Figure 1A).
We then assessed the homogeneity of the samples within each group. First, the number of shared proteins among the samples in each group with respect to the total number of proteins identified in the group was analyzed. The seven NKF samples shared up to 28 proteins of a total of the 394 in the group (7.1%). Five CNIT patients shared up to 143 of 621 proteins (23.0%), and five IFTA patients shared 64 of 512 proteins (12.5%). In total, 17 proteins were shared among all samples analyzed (Figure 1B).

Second, we performed a multiple correlation analysis among samples included in each group as a measure of intragroup homogeneity. Each sample’s protein expression was compared with every other sample in the same group to obtain the mean of all Pearson correlation coefficient. NKF and CNIT groups were the most homogeneous (mean Pearson coefficient > 0.6) (Figure 2A,B). Conversely, the IFTA group showed a lower level of internal homogeneity (barely > 0.5) (Figure 2C). In this group, sample I13 presented a low Pearson coefficient when individually tested with every other IFTA sample (Pearson coefficients < 0.400), suggesting a particular behavior, as observed later. Of note, if I13 sample was not considered in this assay, the mean Pearson coefficient of IFTA samples increased to 0.654, a value similar to that obtained in the CNIT group.

Figure 1. (A) Number of proteins found by mass-spectrometry in uEV samples in each group. Whiskers represent minimum to maximum; horizontal line represents the mean (** *p < 0.01). (B) Venn diagram showing the number of coinciding proteins between the samples of each group (in brackets) and between the all the samples in the study (number in the corresponding circles). On the right, list of the 17 proteins found in all samples.

Figure 2. Multi-scatter plots showing correlations of samples within each group: (A), NKF; (B), CNIT; and (C), IFTA. In each individual plot the Pearson correlation coefficients are shown in blue and the corresponding mean ± sd for each group is shown in black.
2.3. Differentially Expressed Proteins

A principal component analysis (PCA) was performed in order to get more insight onto the global protein variation in the two renal alterations (CNIT and IFTA) and the NKF groups (Figure 3A). CNIT patients were clearly segregated from IFTA and NKF patients by Component 1, which accounted for a 23.9% of the variability among samples, while Component 2, which accounted for 17.1% of the variability, permitted to segregate the three groups of samples. Only the sample of the IFTA group (I13), which had a low correlation with the other IFTA samples, did not cluster together with the rest of samples in its group.

![PCA biplot](image)

Figure 3. (A) Principal component analysis (PCA) biplot that shows distribution of samples according to Components 1 and 2. Each circle represents a sample, which are labelled and colored according to their group. Volcano plots depict the differentially expressed proteins (B) between CNIT and NKF, and (C) between CNIT and IFTA. Each circle represents a protein. On y-axis \(-\log(p\text{-value})\) from a t-test is represented, with a dashed line at \(p < 0.01\) to indicate significance, over which proteins are colored in orange. The expression fold change is represented on the x-axis, with dashed lines at >10 and <10.

Based on this observation, a more concise comparison was performed using a volcano plot to depict the proteins that were significantly overexpressed between groups. Those proteins having \(p < 0.01\) and fold change \(>10\) or \(<-10\) in each comparison were considered as more relevant. From 71 proteins found more expressed in CNIT samples compared to NKF samples (Figure 3B), three (CTSZ, RAB8A and SERPINC1) showed a notable low \(p\)-value (<\(10^{-8}\)). On the other hand, up to 39 proteins were significantly more expressed in the CNIT group compared to IFTA patients (Figure 3C), among which five proteins (ADIRF, CAPG, STXBP2, GNAI1, and ATP1A1) presented a remarkably lower \(p\)-value (<\(10^{-7}\)). Of note, no proteins were overexpressed in the NKF group and only three proteins (HIST1H4A, HRG, and IGHV4-28) were significantly more expressed in the IFTA group versus CNIT. The full list of significant proteins from the volcano plots can be seen in Supplementary Tables S4 and S5.

2.4. Biological Processes Enrichment Analysis

After identifying significant proteins differentially expressed in CNIT, the GSEA software was used to reveal the GO biological processes that were up- or downregulated in this group compared to the other groups (each gene being equivalent to a protein). A total of 45 gene sets were significantly enriched (nominal \(p\)-value < 0.05) in CNIT compared to NKF. None of them reached the minimal significant false discovery rate (FDR) of 0.25, probably because of the dimension of the difference in
protein numbers and level of expression. Nevertheless, the most overexpressed gene set was “Negative regulation of immune response” (Supplementary Tables S6 and S7).

When comparing CNIT and IFTA, up to 128 gene sets were significantly upregulated (FDR < 0.25) in CNIT patients (Supplementary Table S8). The most overexpressed gene sets were “epithelial cell differentiation” and “regulation of actin filament length” (Figure 4A). In addition, CNIT presented overexpression of vesicle-related gene sets such as “vesicle organization” or “multivesicular body organization.” Other gene sets more expressed in CNIT than in IFTA were “cell cycle” and “intracellular protein transport.”

![Figure 4](image_url)

**Figure 4.** Enrichment plots from GSEA conducted with GO-BP gene sets, each gene accounting for one protein. Statistically significant up-regulation of (A) “epithelial cell differentiation” and “regulation of actin filament length” was found in CNIT when compared with IFTA (to the left of the x-axis, positive running enrichment score (ES)). (B) “Protein activation cascade” and “humoral immune response” were found up-regulated in IFTA compared to CNIT (to the right of the x-axis, negative ES). Vertical black lines indicate the position of individual genes of the gene set in the ranked list. Heatmap on the right of each plot show the relative expression level of the most up-regulated genes of the gene set (red = high, blue = low). NES, normalized enrichment score; FDR, false discovery rate; p-val, p-value.

On the reverse comparison, 59 gene sets were upregulated in IFTA compared to CNIT (Supplementary Table S9), “protein activation cascade” and “humoral immune response” (Figure 4B) being two of the most significant ones. Other gene sets related to inflammatory response and complement activation were also upregulated.

Interestingly, several proteins of the uroplakin family (UPK1A, UPK1B, UPK2, and UPK3A), as well as envoplakin (EVPL) and periplakin (PPL) (citolinker proteins) were significantly upregulated in CNIT compared to IFTA and NKF (Figure 5). These proteins are members of the “epithelial cell differentiation” gene set.
Figure 4. Enrichment plots from GSEA conducted with GO-BP gene sets, each gene accounting for one protein. Statistically significant up-regulation of (A) "epithelial cell differentiation" and "regulation of actin filament length" was found in CNIT when compared with IFTA (to the left of the x-axis, positive enrichment score (ES)). (B) "Protein activation cascade" and "humoral immune response" were found up-regulated in IFTA compared to CNIT (to the right of the x-axis, negative ES). Vertical black lines indicate the position of individual genes of the gene set in the ranked list. Heatmap on the right of each plot show the relative expression level of the most up-regulated genes of the gene set (red = high, blue = low). NES, normalized enrichment score; FDR, false discovery rate; p-value.

Interestingly, several proteins of the uroplakin family (UPK1A, UPK1B, UPK2, and UPK3A), as well as envoplakin (EVPL) and periplakin (PPL) (citolinker proteins) were significantly upregulated in CNIT compared to IFTA and NKF (Figure 5). These proteins are members of the "epithelial cell differentiation" gene set.

Figure 5. Expression profile of seven proteins of the uroplakin and plakin families. Whiskers represent minimum to maximum; horizontal line represents the mean. UPK1A, uroplakin 1A; UPK1B, uroplakin 1B; UPK2, uroplakin 2; UPK3A, uroplakin 3A; UPK3B, uroplakin 3B; EVPL, envoplakin; PPL, periplakin. * p < 0.05; ** p < 0.01; *** p < 0.001.

3. Discussion

CNIT in kidney-transplantation is controversial. In this study, the uEV proteome of kidney-transplanted patients diagnosed with CNIT was analyzed and compared to either kidney-transplanted patients with clinically normal kidney function or diagnosed with IFTA without CNIT, all of them receiving a similar immunosuppressive regime including CNI. Expectedly, both CNIT and IFTA patients presented a significantly higher serum creatinine than NKF patients.

A first characterization of all the proteins found by mass-spectrometry showed that there was an enrichment of proteins related to the secretion of EV, which denotes the efficacy of uEV enrichment performed using SEC. An efficient EV purification is key to greatly diminish the interference of abundant soluble proteins (especially uromodulin) for a mass-spectrometry analysis, contributing to the detection of lower abundance proteins that may be potential biomarkers [23–25].

The PCA-based comparison of the proteomic results could clearly separate the three groups of samples, indicating that the uEV proteome follows different patterns in NKF, CNIT, and IFTA. Only sample I13, which showed a low correlation coefficient with the other samples within its group, did not cluster as the other IFTA samples did. A possible explanation for this observation could be the two previous episodes of rejection that I13 patient had suffered within 2 years before sample collection. Yet, as no signs of rejection were observed in the biopsy performed at the time of urine sample collection, the patient was finally included in the assay. Our results may suggest those rejection episodes do seem to be still reflected in the uEV proteome. Also interestingly, although chronic CNIT can present lesions compatible with an IFTA diagnosis at the histological level [26], sample C10 did not cluster with IFTA samples. In fact, despite being the unique CNIT sample diagnosed of a chronic CNIT instead of acute CNIT, there was no apparent segregation of C10 from the other CNIT samples in the PCA, pointing to the resemblance of the pathological process in both chronic and acute cases, at least at the uEV proteomic level. Yet, as this study has been performed on a limited number of samples, these results have to be cautiously interpreted.

Vesicle-related gene sets were significantly overexpressed in the CNIT group. Some studies have described that acute CNIT can cause tubular epithelial cell cytoplasmic small vacuoles and abundant lysosomes due to dilatations of the smooth endoplasmic reticulum by aqueous fluid [10–12]. Moreover, it has been shown that a pathological process, like CNIT, increases the secretion activity of kidney cells [27]. Hypothetically, some of these vesicles may be released into the lumen of the proximal tubules and then in urine, so they would be captured as extracellular vesicles, thus increasing the number of proteins found in the proteomic analysis in CNIT samples, as we report here.
In renal biopsies, CNIT often show features shared with IFTA lesions. Both cyclosporin-A and tacrolimus are directly responsible of the increase of TGF-β1 [28], a factor that promotes interstitial fibrosis by increasing synthesis of proteins of the extracellular matrix and decreasing their degradation [29,30]. Moreover, TGF-β1 induces epithelium-to-mesenchymal transition at the tubular level leading to fibrosis by the generation of myofibroblasts [31,32]. Also, it has been shown that CNI drugs induce apoptosis on tubular and interstitial cells in vitro [33,34]. The GSEA analysis show overexpression of different gene sets in CNIT compared to IFTA as well as NKF, suggesting the activation of specific mechanisms in CNIT. Specifically, the proteome of CNIT was significantly enriched in gene sets related to epithelial cell differentiation, probably because of the death of tubular epithelial cells that force their regeneration. Members of the uroplakin family (UPK1A, UPK1B, UPK2, and UPK3A) were also overexpressed in CNIT compared to IFTA. Uroplakins are transmembrane proteins that bind to each other to form a plaque on the surface of the urothelium to prevent influx of urine from the lumen, which covers the renal pelvis, ureters, urinary bladder, and prostatic urethra [35]. The molecular weight of uroplakins ranges from 15 to 47 kDa, suggesting their intravesicular location [36]. Periplakin and envoplakin, two other members of the plakin family that function as cell-linker proteins, were also found enriched in CNIT [37]. These two proteins present a larger molecular weight of around 200 kDa and would possibly elute in the uEV-enriched fractions of SEC as free proteins instead of being carried by uEV [38,39]. Salih et al. described that patients in advanced stages of autosomal dominant polycystic kidney disease (ADPKD) presented increased levels of periplakin and envoplakin in their uEV [40]. In our study, only one patient in the CNIT group (C11) was diagnosed with ADPKD, but all the other CNIT samples also presented high levels of periplakin and envoplakin. The higher abundance of plakins in CNIT uEV suggests that the toxic effect of CNI on the urothelium may increase citolinker proteins’ activity and this would be reflected in a higher presence in their uEV. Therefore, plakin family members could represent promising biomarkers for CNIT in uEV.

Conversely, the CNIT uEV proteome did not reflect genes related to protein activation cascade and humoral response as well as other inflammatory processes when compared to IFTA. The reason behind could be that patients in the CNIT group had higher serum levels of CNI [21] which could be responsible for an increased capacity to suppress the inflammatory response.

Only a few studies using proteomic approaches have defined the effect of CNIT on kidneys. Sidgel et al. [41] investigated the urinary proteome of kidney-transplanted pediatric patients with different pathologies, including CNIT. They found a panel of ten proteins that potentially differentiated CNIT from chronic allograft nephropathy, although none of them coincided with our results, most probably because of the differences between using whole urine or uEV. Other groups studied the effect of CNI on renal cell lines in vitro [42,43]. They found that CNI caused an increase in endoplasmic reticulum stress, mitochondrial apoptosis, and involvement of the phosphatidylinositol 3-kinases (PI3K), metalloproteinases (MMP), protein kinase C (PKC), and glycogen synthase kinase 3 (GSK3) pathways. To our best knowledge, our study is the first to analyze the uEV proteome of kidney-transplanted patients diagnosed of CNIT.

There is a lack of knowledge on how CNIT develops in renal transplanted patients despite the wide use of CNI and their contribution to kidney graft loss. Thus, a better knowledge of the effect of CNI at the renal level is of utmost importance for the detection and management in patients undertaking kidney transplantation. Although no conclusive biomarkers can be asserted from this single pilot study, we found a higher expression of proteins from the plakin family in the CNIT group, which may be envisaged as promising biomarkers and merit future investigation. This work adds further evidence to the potential of uEV as a source of non-invasive protein biomarkers for the better detection and monitoring of this renal alteration in kidney-transplanted patients.
4. Materials and Methods

4.1. Patients and Pre-Processing of Samples

Urine samples were collected from kidney-transplanted patients classified into three groups: normal kidney function (NKF) ($n = 7$) as determined by analytical parameters (creatinemia and proteinuria), CNIT ($n = 5$), and interstitial fibrosis tubular atrophy (IFTA) ($n = 5$), both diagnosed by analytical parameters and by per-cause renal biopsy. Patients classified in the IFTA group had a biopsy diagnosis of IFTA in the absence of any other cause. None of the patients presented C4d deposits in the renal biopsy. Morning mid-stream urine was collected immediately before per-cause renal biopsy (in the case of alteration of serum creatinine and proteinuria). Inclusion criteria were male or female patients older than 18 years of age and ability to give informed consent. Exclusion criteria were hematuria or urinary tract infection demonstrated by the presence of leukocyturia and/or bacteriuria and a previous kidney transplantation. All patients were receiving a similar immunosuppressive regime including CNI. This study was performed in line with the principles of the Declaration of Helsinki [44]. Approval was granted by the Ethics Committee “Comité d’Ética de la investigació clínica de l’Hospital Universitari Germans Trias i Pujol” and in accordance with its recommendations of the Guideline for Good Clinical Practice. Informed consent was obtained from all individual participants included in the study. An arbitrary number was used to label samples to protect patients’ identity.

4.2. Samples Processing and uEV Isolation

Urine samples were centrifuged (600× g 15 min) to eliminate cells and debris and stored at −80 °C with protease inhibitor (AEBSF, 0.138 mg/mL; Roche, Basel, Switzerland). Urinary EV (uEV) were isolated following the procedure described by Monguíó-Tortajada et al. [45]. In brief, urine samples (140 mL) were thawed overnight at 4 °C and centrifuged at 17,000× g for 10 min. The pellet was treated with 1,4-dithiothreitol (200 mg/mL; Sigma-Aldrich, St. Louis, MO, USA) to disrupt Tamm-horse fall protein polymers before mixing it with the initial supernatant and centrifuging again at 17,000× g for 10 min. Then, the supernatant was concentrated through a Centricon filter unit of 100 kDa cut-off (Millipore, Bedford, MA, USA) down to 1–2 mL. One mL of the concentrate was loaded onto a SEC column with 12 mL of sepharose CL-2B (Sigma-Aldrich) and 20 fractions of 500 µL were collected using phosphate-buffered saline (PBS; Sigma-Aldrich) as elution agent. Protein elution of SEC fractions was determined by reading absorbance at 280 nm with Nanodrop ND-1000 (Thermo Scientific, Waltham, MA, USA). In addition, SEC fractions were analyzed for their CD9 and CD63 content (typical tetraspanin EV markers) using beads-based assay flow cytometry. The three fractions with the highest CD9 and CD63 mean fluorescence intensity (MFI) intensity were pooled together rendering a volume of approximately 1.5 mL of uEV-enriched samples.

4.3. Mass-Spectrometry

Five hundred µL of uEV-enriched samples were used for the mass-spectrometry analysis (LC-MS/MS) on an Orbitrap XL (Thermo Scientific). Proteins were digested using LysC and Trypsin (Promega, Madison, WI, USA) and BSA (Sigma-Aldrich) solutions were included as quality controls. Data were analyzed using the Proteome Discoverer software (v2.0; Thermo Scientific) and proteins were identified using Mascot (Matrix Science, London, UK) against the SwissProt human database (UniProt, April 2015; https://www.uniprot.org/) [46] with an FDR of 0.05. The resulting raw data files were processed using the MaxQuant software [47] (version 1.5.3.30) against the SwissProt human database (UniProt, December 2015) applying a maximum FDR of 1%. Intensity-based absolute quantification (iBAQ) values normalized with the EV marker ezrin were used for subsequent analyses.

4.4. Proteomics and Statistical Analysis

The FunRich software (http://www.funrich.org, Melbourne, Australia) [48,49] was used to perform some of the GO enrichment analyses. Overlapping proteins were calculated and visualized with
the online tool InteractiVenn (http://www.interactivenn.net) [50]. The Perseus software [51] (v1.5.6.0; http://www.perseus-framework.org, Max Planck Institute of Biochemistry, Martinsried, Germany) and GraphPad Prism software (v6.0 GraphPad Software, San Diego, CA, USA) were used for the creation of plots and the statistical analysis. After testing for normality, two-sided unpaired t-test (parametric) or Mann-Whitney test (non-parametric) were used for the comparison of two groups of samples; in the case of multiple-groups comparison, one way ANOVA with Holm-Sidak's multiple comparison test (parametric) or Kruskall-Wallis with Dunn's multiple comparison test (non-parametric) were performed. Finally, the Gene Set Enrichment Analysis software (GSEA v3.0, Broad Institute, Cambridge, MA, USA) [52] was used to compare the enrichment of gene sets, which were downloaded from the GSEA Molecular Signatures Database (MSigDB v6.2, Broad Institute, Cambridge, MA, USA) [53]. The normalized enrichment score (NES) accounts for differences between gene sets to allow comparisons between them. The FDR represents the nominal p-value adjusted for gene set size and multiple hypothesis testing. It is the estimated probability that a gene set with a given NES represents a false positive finding (significant FDR < 0.25, as recommended by the GSEA software).

5. Patents

LCP, RL and FEB have a European Patent Application pending for the present work.

Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/21/20/7569/s1.

Author Contributions: Conceptualization, R.L. and F.E.B.; samples acquisition, O.T., L.C., and J.J.; software, L.C.-P.; formal analysis, L.C.-P. and F.E.B.; writing—original draft preparation, L.C.-P.; writing—review and editing, O.T., L.C., J.J., M.F., R.L., and F.E.B.; project administration, R.L. and F.E.B.; funding acquisition, F.E.B. All authors have read and agreed to the published version of the manuscript.

Funding: This work was supported in part by grants from project PI13/00050 integrated in the National R+D+i and funded by the ISCIII and the European Regional Development Fund (http://www.isciii.es), the SGR program of Generalitat de Catalunya (2017-SGR-301 REMAR Group), the ISCIII-REDinREN (RD16/0009 Feder Funds), and Fundació Cellex. The project leading to these results has also received funding from “la Caixa” Foundation (ID 100010434), under agreement LCF/TR/CI19/52460021. This activity has received funding from the European Institute of Innovation and Technology (EIT). This body of the European Union receives support from the European Union’s Horizon 2020 research and innovation program. LCP is sponsored by the Spanish Government FPU grant (“Formació de Personal Universitario”, FPU17/01444). MF is supported by ISCIII (MS19/00018), co-funded by ERDF/ESF, “Investing in your future”. FEB is a researcher from Fundació Institut de Recerca en Ciències de la Salut Germans Trias i Pujol, supported by the Health Department of the Catalan Government (Direcció General de Recerca i Innovació, Dept. Salut, Generalitat de Catalunya).

Acknowledgments: We are indebted to Miriam Morón-Font for her valuable technical help. Paula Rodríguez Martínez from the Histopathology Department of the Germans Trias i Pujol University Hospital for the biopsy histological images. The authors would also like to thank Yañez-Mó (Unidad de Investigacion, Hospital Sta Cristina, IIS-IP; Departamento Biología Molecular/CBM-SO, UAM) and Francisco Sánchez-Madrid (Servicio de Inmunología, Hospital Universitari de la Princesa, IIS-IP, UAM; Cell-cell Communication Laboratory, CNIC) for the anti-CD9 and anti-CD63 antibodies. Also, thanks to Marco A. Fernández from the Flow Cytometry Platform, IGTP.

Conflicts of Interest: LCP, RL, and FEB have a European Patent Application pending for the present work. The other authors declare no conflict of interest.

Abbreviations

| Term | Description |
|------|-------------|
| aCNIT | acute calcineurin inhibitors toxicity |
| ANOVA | Analysis of variance |
| BP | Biological Process |
| CC | Cellular Component |
| cCNIT | chronic calcineurin inhibitors toxicity |
| CD | cluster of differentiation |
| CNI | calcineurin inhibitors |
| CNIT | calcineurin inhibitors toxicity |
| CSA | cyclosporine A |
References

1. Heusler, K.; Pletscher, A. The controversial early history of cyclosporin. Swiss Med. Wkly. 2001, 131, 299–302. [CrossRef] [PubMed]
2. Calne, R. Cyclosporine as a milestone in immunosuppression. Transplant. Proc. 2004, 36, 13S–15S. [CrossRef]
3. Kino, T.; Hatanaka, H.; Hashimoto, M.; Nishiyama, M.; Goto, T.; Okuhara, M.; Kohsaka, M.; Aoki, H.; Imanaka, H. FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics. J. Antibiot. 1987, 40, 1249–1255. [CrossRef] [PubMed]
4. Hatanaka, H.; Iwami, M.; Kino, T.; Goto, T.; Okuhara, M. FR-900520 and FR-900523, novel immunosuppressants isolated from a Streptomyces. I. Taxonomy of the producing strain. J. Antibiot. 1988, 41, 1586–1591. [CrossRef] [PubMed]
5. Starzl, T.E.; Todo, S.; Fung, J.; Demetris, A.J.; Venkataramman, R.; Jain, A. FK 506 for liver, kidney, and pancreas transplantation. Lancet 1989, 2, 1000–1004. [CrossRef]
6. Martinez-Martinez, S.; Redondo, J.M. Inhibitors of the calcineurin/NFAT pathway. Curr. Med. Chem. 2004, 11, 997–1007. [CrossRef]
7. Andreoni, K.A.; Brayman, K.L.; Guidinger, M.K.; Sommers, C.M.; Sung, R.S. Kidney and pancreas transplantation in the United States, 1996–2005. Am. J. Transplant. 2007, 7, 1359–1375. [CrossRef]
8. Azzi, J.R.; Sayegh, M.H.; Mallat, S.G. Calcineurin inhibitors: 40 years later, can’t live without . . . . J. Immunol. 2013, 191, 5785–5791. [CrossRef]
9. Issa, N.; Kukla, A.; Ibrahim, H.N. Calcineurin inhibitor nephrotoxicity: A review and perspective of the evidence. Am. J. Nephrol. 2013, 37, 602–612. [CrossRef]
10. Liptak, P.; Ivanyi, B. Primer: Histopathology of calcineurin-inhibitor toxicity in renal allografts. Nat. Clin. Pract. Nephrol. 2006, 2, 398–404. [CrossRef]
11. Charney, D.A.; Bhaskaran, M.; Molmenti, E. Calcineurin inhibitor toxicity in a renal transplant recipient. *Clin. Kidney J.* 2009, 2, 175–176. [CrossRef] [PubMed]

12. Fogo, A.B.; Lusco, M.A.; Najafian, B.; Alpers, C.E. AJKD Atlas of renal pathology: Osmotic tubular injury. *Am. J. Kidney Dis.* 2017, 69, e11–e12. [CrossRef] [PubMed]

13. Nankivell, B.J.; Fenton-Lee, C.A.; Kuypers, D.R.; Cheung, E.; Allen, R.D.; O’Connell, P.J.; Chapman, J.R. Effect of histological damage on long-term kidney transplant outcome. *Transplantation* 2001, 71, 515–523. [CrossRef]

14. Leal, R.; Tsapepas, D.; Crew, R.J.; Dube, G.K.; Ratner, L.; Batal, I. Pathology of calcineurin and mammalian target of rapamycin inhibitors in kidney transplantation. *Kidney Int. Rep.* 2018, 3, 281–290. [CrossRef] [PubMed]

15. Naesens, M.; Lerut, E.; Damme, B.V.; Vanrenterghem, Y.; Kuypers, D.R.J. Tacrolimus exposure and evolution of renal allograft histology in the first year after transplantation. *Am. J. Transplant.* 2007, 7, 2114–2123. [CrossRef] [PubMed]

16. Serón, D.; Moreso, F.; Fulladosa, X.; Hueso, M.; Carrera, M.; Grinyó, J.M. Reliability of chronic allograft nephropathy diagnosis in sequential protocol biopsies. *Kidney Int.* 2002, 61, 727–733. [CrossRef]

17. Kershner, R.P.; Fitzsimmons, W.E. Relationship of FK506 whole blood concentrations and efficacy and toxicity after liver and kidney transplantation. *Transplantation* 1996, 62, 920–926. [CrossRef]

18. Hesselink, D.A.; Bouamar, R.; van Gelder, T. The pharmacogenetics of calcineurin inhibitor-related nephrotoxicity. *Therap. Drug Monit.* 2010, 32, 387–393. [CrossRef]

19. Thölking, G.; Schütte-Nütgen, K.; Schmitz, J.; Rovas, A.; Dahmen, M.; Bautz, J.; Jehn, U.; Pavenstädter, H.; Heitplatz, B.; Van Marck, V.; et al. A low tacrolimus concentration/dose ratio increases the risk for the development of acute calcineurin inhibitor-induced nephrotoxicity. *J. Clin. Med.* 2019, 8, 1586. [CrossRef]

20. Yañez-Mó, M.; Siljander, P.R.-M.; Andreu, Z.; Bedina Zavec, A.; Borrás, F.E.; Buzas, E.I.; Buzas, K.; Casal, E.; Cappello, F.; Carvalho, J.; et al. Biological properties of extracellular vesicles and their physiological functions. *J. Extracell. Vesicles* 2015, 4, 27066. [CrossRef]

21. Cosio, F.G.; Amer, H.; Grande, J.P.; Larson, T.S.; Stegall, M.D.; Griffin, M.D. Comparison of low versus high tacrolimus levels in kidney transplantation: Assessment of efficacy by protocol biopsies. *Transplantation* 2007, 83, 411–416. [CrossRef] [PubMed]

22. Ekberg, H.; Grinyó, J.; Nasan, B.; Vanrenterghem, Y.; Vincenti, F.; Voulgari, A.; Truman, M.; Nasmyth-Miller, C.; Rashford, M. Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: The CAESAR Study. *Am. J. Transplant.* 2007, 7, 560–570. [CrossRef] [PubMed]

23. An, M.; Wu, J.; Zhu, J.; Lubman, D.M. Comparison of an Optimized Ultracentrifugation Method versus Size-Exclusion Chromatography for Isolation of Exosomes from Human Serum. *J. Proteome Res.* 2018, 17, 3599–3605. [CrossRef] [PubMed]

24. Benediktner, B.J.; Bouwman, F.G.; Vajen, T.; Heinzmann, A.C.A.; Grauls, G.; Mariman, E.C.; Wouters, E.F.M.; Savelkoul, P.H.; Lopez-Iglesias, C.; Koenen, R.R.; et al. Ultrafiltration combined with size exclusion chromatography efficiently isolates extracellular vesicles from cell culture media for compositional and functional studies. *Sci. Rep.* 2017, 7, 1–13. [CrossRef]

25. Gámez-Valero, A.; Monguio-Tortajada, M.; Carreras-Planella, L.; Franquesa, M.; Beyer, K.; Borrás, F.E. Size-Exclusion Chromatography-based isolation minimally alters Extracellular Vesicles’ characteristics compared to precipitating agents. *Sci. Rep.* 2016, 6, 33641. [CrossRef]

26. Schwarz, A.; Haller, H.; Schmitt, R.; Schiffer, M.; Koenecke, C.; Strassburg, C.; Lehner, F.; Gottlieb, J.; Bara, C.; Becker, J.U.; et al. Biopsy-diagnosed renal disease in patients after transplantation of other organs and tissues. *Am. J. Transplant.* 2010, 10, 2017–2025. [CrossRef]

27. Wang, X.; Wilkinson, R.; Kildey, K.; Potriquet, J.; Mulvenna, J.; Lobb, R.J.; Möller, A.; Cloonan, N.; Mukhopadhyay, P.; Kassianos, A.J.; et al. Unique molecular profile of exosomes derived from primary human proximal tubular epithelial cells under diseased conditions. *J. Extracell. Vesicles* 2017, 6, 1314073. [CrossRef]

28. Khanna, A.; Plummer, M.; Bromberek, C.; Bresnahan, B.; Hariharan, S. Expression of TGF-beta and fibrogenic genes in transplant recipients with tacrolimus and cyclosporine nephrotoxicity. *Kidney Int.* 2002, 62, 2257–2263. [CrossRef]

29. Farris, A.B.; Colvin, R.B. Renal interstitial fibrosis: Mechanisms and evaluation. *Curr. Opin. Nephrol. Hypertens.* 2012, 21, 289–300. [CrossRef]
30. Gewin, L.; Zent, R. How does TGF-β mediate tubulointerstitial fibrosis? *Semin. Nephrol.* 2012, 32, 228–235. [CrossRef]

31. Grgic, I.; Duffield, J.S.; Humphreys, B.D. The origin of interstitial myofibroblasts in chronic kidney disease. *Pediatr. Nephrol.* 2012, 27, 183–193. [CrossRef]

32. Canew, R.M.; Wang, B.; Kantharidis, P. The role of EMT in renal fibrosis. *Cell Tissue Res.* 2012, 347, 103–116. [CrossRef] [PubMed]

33. Puigmüller, M.; López-Hellín, J.; Suñé, G.; Tornavaca, O.; Camaño, S.; Tejedor, A.; Meseguer, A. Differential proteomic analysis of cyclosporine A-induced toxicity in renal proximal tubule cells. *Nephrol. Dial. Transplant.* 2009, 24, 2672–2686. [CrossRef] [PubMed]

34. Xiao, Z.; Li, C.; Shan, J.; Luo, L.; Feng, L.; Lu, J.; Li, S.; Long, D.; Li, Y. Mechanisms of renal cell apoptosis induced by cyclosporine A: A systematic review of in vitro studies. *Am. J. Nephrol.* 2011, 33, 558–566. [CrossRef] [PubMed]

35. Jenkins, D.; Woolf, A.S. Uropelakins: New molecular players in the biology of urinary tract malformations. *Kidney Int.* 2007, 71, 195–200. [CrossRef] [PubMed]

36. Min, G.; Wang, H.; Sun, T.-T.; Kong, X.-P. Structural basis for tetraspanin functions as revealed by the cryo-EM structure of uroplakin complexes at 6-Å resolution. *J. Cell Biol.* 2006, 173, 975–983. [CrossRef] [PubMed]

37. Karashima, T. Interaction of periplakin and envoplakin with intermediate filaments. *J. Cell Sci.* 2002, 115, 5027–5037. [CrossRef] [PubMed]

38. Ruhrberg, C.; Hajibagheri, M.A.; Simon, M.; Dooley, T.P.; Watt, F.M. Envoplakin, a novel precursor of the cornified envelope that has homology to desmoplakin. *J. Cell Biol.* 1996, 134, 715–729. [CrossRef]

39. Ruhrberg, C.; Hajibagheri, M.A.N.; Parry, D.A.D.; Watt, F.M. Periplakin, a Novel Component of Cornified Envelopes and Desmosomes That Belongs to the Plakin Family and Forms Complexes with Envoiplakin. *J. Cell Biol.* 1997, 139, 1835–1849. [CrossRef]

40. Salih, M.; Demmers, J.A.; Beszstarosti, K.; Leonhard, W.N.; Losekoot, M.; van Kooten, C.; Gansevoort, R.T.; Peters, D.J.M.; Zietse, R.; Hoorn, E.J. Proteomics of urinary vesicles links plakins and complement to polycystic kidney disease. *J. Am. Soc. Nephrol.* 2017, 28, 3079–3092. [CrossRef] [PubMed]

41. Sigdel, T.K.; Sarwal, M.M. Assessment of circulating protein signatures for kidney transplantation in pediatric recipients. *Front. Med.* 2017, 4, 80. [CrossRef] [PubMed]

42. Sarró, E.; Jacobs-Cachá, C.; Itarte, E.; Meseguer, A. A pharmacologically-based array to identify targets of cyclosporine A-induced toxicity in cultured renal proximal tubule cells. *Toxicol. Appl. Pharmacol.* 2012, 258, 275–287. [CrossRef] [PubMed]

43. Lamoureux, F.; Mestre, E.; Essig, M.; Sauvage, F.L.; Marquet, P.; Gastinel, L.N. Quantitative proteomic analysis of cyclosporine-induced toxicity in a human kidney cell line and comparison with tacrolimus. *J. Proteom.* 2011, 75, 677–694. [CrossRef] [PubMed]

44. Løynæ, N.; Sandlund, M.; Dahlqvist, G.; Jacobsson, L. Informed consent: Study of quality of information given to participants in a clinical trial. *BMJ* 1991, 303, 610–613. [CrossRef]

45. Monguio-Tortajada, M.; Morón-Font, M.; Gámez-Valero, A.; Carreras-Planella, L.; Borràs, F.E.; Franquesa, M. Extracellular-Vesicle Isolation from Different Biological Fluids by Size-Exclusion Chromatography. *Curr. Protoc. Stem Cell Biol.* 2019, 49, e82. [CrossRef] [PubMed]

46. The UniProt Consortium UniProt: A worldwide hub of protein knowledge. *Nucleic Acids Res.* 2019, 47, D506–D515. [CrossRef]

47. Cox, J.; Mann, M. MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. *Nat. Biotechnol.* 2006, 24, 1669–1676. [CrossRef]

48. Pathan, M.; Keerthikumar, S.; Ang, C.-S.; Gangoda, L.; Quek, C.Y.J.; Williamson, N.A.; Mouradov, D.; Sieber, O.M.; Simpson, R.J.; Salim, A.; et al. FunRich: An open access standalone functional enrichment and interaction network analysis tool. *Proteomics* 2015, 15, 2597–2601. [CrossRef]

49. Pathan, M.; Keerthikumar, S.; Chisanga, D.; Alessandro, R.; Ang, C.-S.; Askenase, P.; Batagov, A.O.; Benito-Martin, A.; Camussi, G.; Clayton, A.; et al. A novel community driven software for functional enrichment analysis of extracellular vesicles data. *J. Extracell. Vesicles* 2017, 6, 1321455. [CrossRef]

50. Heberle, H.; Meirelles, G.V.; da Silva, F.R.; Telles, G.P.; Minghim, R. InteractiVenn: A web-based tool for the analysis of sets through Venn diagrams. *BMC Bioinform.* 2015, 16, 169. [CrossRef]

51. Pathan, M.; Keerthikumar, S.; Ang, C.-S.; Gangoda, L.; Quek, C.Y.J.; Williamson, N.A.; Mouradov, D.; Sieber, O.M.; Simpson, R.J.; Salim, A.; et al.
51. Tyanova, S.; Temu, T.; Sinitcyn, P.; Carlson, A.; Hein, M.Y.; Geiger, T.; Mann, M.; Cox, J. The Perseus computational platform for comprehensive analysis of (prote)omics data. Nat. Methods 2016, 13, 731–740. [CrossRef] [PubMed]

52. Subramanian, A.; Tamayo, P.; Mootha, V.K.; Mukherjee, S.; Ebert, B.L.; Gillette, M.A.; Paulovich, A.; Pomeroy, S.L.; Golub, T.R.; Lander, E.S.; et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 2005, 102, 15545–15550. [CrossRef] [PubMed]

53. Liberzon, A.; Subramanian, A.; Pinchback, R.; Thorvaldsdottir, H.; Tamayo, P.; Mesirov, J.P. Molecular signatures database (MSigDB) 3.0. Bioinformatics 2011, 27, 1739–1740. [CrossRef] [PubMed]

**Publisher’s Note:** MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).